PharmExec articleshttps://www.pharmexec.com/newsPharmExec articles© 2026 MJH Life Sciences™ and PharmExec. All rights reserved.Thu, 09 Apr 2026 23:23:33 +00005en-us14447https://www.pharmexec.com/newshttps://www.pharmexec.com/logo.webphttps://www.pharmexec.com/view/daily-shionogi-receives-contract-through-barda-project-bioshieldhttps://www.pharmexec.com/view/daily-shionogi-receives-contract-through-barda-project-bioshield<![CDATA[In today's Pharmaceutical Executive Daily, Shionogi receives a contract worth up to $482 million to bolster U.S. preparedness against drug-resistant bacterial threats, Roche and C4 Therapeutics expand their long-standing partnership into a new collaboration to develop degrader-antibody conjugates for oncology, and Pharmaceutical Executive profiles AstraZeneca CFO Aradhana Sarin on how she approaches the role as a strategic catalyst for growth.]]>Thu, 09 Apr 2026 19:15:16 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/aradhana-sarin-the-cfo-as-a-catalysthttps://www.pharmexec.com/view/aradhana-sarin-the-cfo-as-a-catalyst<![CDATA[In becoming the first CFO to be named HBA Woman of the Year, AstraZeneca's Aradhana Sarin highlights how financial leadership now sits at the center of innovation, access and strategic transformation.]]>Thu, 09 Apr 2026 17:45:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/roche-c4-therapeutics-expands-partnership-billion-collaboration-agreementhttps://www.pharmexec.com/view/roche-c4-therapeutics-expands-partnership-billion-collaboration-agreement<![CDATA[C4 Therapeutics and Roche expanded their partnership to develop next-generation degrader-antibody conjugates, a novel oncology approach designed to improve the precision and therapeutic index of traditional antibody-drug conjugates.]]>Thu, 09 Apr 2026 14:09:12 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/shionogi-inc-awarded-482-million-contract-us-government-enhance-national-preparedness-drug-resistant-bacterial-threatshttps://www.pharmexec.com/view/shionogi-inc-awarded-482-million-contract-us-government-enhance-national-preparedness-drug-resistant-bacterial-threats<![CDATA[The U.S. government’s contract with Shionogi highlights renewed public-private investment in antimicrobial resistance and biodefense, aiming to strengthen domestic manufacturing and expand the role of novel antibiotics against high-priority threats.]]>Thu, 09 Apr 2026 13:29:59 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/lipid-lowering-pcsk9-inhibition-long-term-efficacy-long-standing-barriershttps://www.pharmexec.com/view/lipid-lowering-pcsk9-inhibition-long-term-efficacy-long-standing-barriers<![CDATA[This disconnect between clinical efficacy and real-world utilization remains one of the most persistent challenges in lipid management.]]>Thu, 09 Apr 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/complexity-obesity-impact-effectiveness-glp1https://www.pharmexec.com/view/complexity-obesity-impact-effectiveness-glp1<![CDATA[Phenomix CEO Mark Bagnall discusses the effectiveness of GLP-1s and how obesity impacts different patients in a variety of complex ways.]]>Thu, 09 Apr 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-shah-capital-plan-vote-against-novavax-board-nomineeshttps://www.pharmexec.com/view/daily-shah-capital-plan-vote-against-novavax-board-nominees<![CDATA[In today's Pharmaceutical Executive Daily, activist investor Shah Capital escalates its campaign against Novavax's board ahead of the company's annual meeting, a Louisiana federal judge declines to block mail-order access to mifepristone while leaving open the possibility of a future ruling against it, and a Q&amp;A examines how the pharmaceutical industry is navigating the compounding pressures of the Iran war and tariff uncertainty on global supply chains.]]>Wed, 08 Apr 2026 19:47:42 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/q-a-supply-chain-fallout-from-iran-war-tariff-uncertaintyhttps://www.pharmexec.com/view/q-a-supply-chain-fallout-from-iran-war-tariff-uncertainty<![CDATA[Dan Bell, chief strategy officer at Marken, discusses how biopharma companies and logistics teams are responding to the dual disruptors to global supply chain operations.]]>Wed, 08 Apr 2026 18:43:07 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/why-advisory-committees-remain-essential-in-an-era-of-complex-medicineshttps://www.pharmexec.com/view/why-advisory-committees-remain-essential-in-an-era-of-complex-medicines<![CDATA[Dismissing the role of independent, outside experts in FDA decision-making weakens the drug review process. ]]>Wed, 08 Apr 2026 17:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/louisiana-federal-judge-rules-against-blocking-sending-abortion-pill-mailhttps://www.pharmexec.com/view/louisiana-federal-judge-rules-against-blocking-sending-abortion-pill-mail<![CDATA[A federal court’s decision to temporarily allow continued mail distribution of mifepristone underscores the ongoing legal and regulatory uncertainty surrounding abortion access.]]>Wed, 08 Apr 2026 14:21:30 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/novavax-stock-increases-shah-capital-plans-vote-against-board-nomineeshttps://www.pharmexec.com/view/novavax-stock-increases-shah-capital-plans-vote-against-board-nominees<![CDATA[Shah Capital escalates its pressure campaign against Novavax leadership, requesting changes and strategic overhauls amid ongoing performance concerns. ]]>Wed, 08 Apr 2026 13:35:50 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/unexpected-costs-glp1-patients-facehttps://www.pharmexec.com/view/unexpected-costs-glp1-patients-face<![CDATA[Phenomix CEO Mark Bagnall explains how GLP-1 users often face significant costs to deal with the side effects of GLP-1 usage.]]>Wed, 08 Apr 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/bridging-precision-gap-accelerating-clinical-adoption-companion-diagnostics-oncologyhttps://www.pharmexec.com/view/bridging-precision-gap-accelerating-clinical-adoption-companion-diagnostics-oncology<![CDATA[Companion diagnostics are reshaping precision oncology, but clinical adoption continues to lag behind scientific progress due to regulatory, operational and reimbursement barriers.]]>Wed, 08 Apr 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/medical-supply-chains-risk-over-escalating-conflicts-iran-reporthttps://www.pharmexec.com/view/medical-supply-chains-risk-over-escalating-conflicts-iran-report<![CDATA[Disruptions from the U.S.and Iran conflict moves across key transit routes and threatens the flow of active ingredients, price spikes, and heightened risk of drug shortages worldwide.]]>Tue, 07 Apr 2026 19:50:18 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-wegovy-hd-now-available-ushttps://www.pharmexec.com/view/daily-wegovy-hd-now-available-us<![CDATA[In today's Pharmaceutical Executive Daily, Novo Nordisk launches Wegovy HD nationwide across the U.S., Gilead Sciences agrees to acquire German antibody-drug conjugate biotech Tubulis for up to $5 billion, and Pharmaceutical Executive marks World Health Day 2026 with a collection of voices from industry leaders on what it means to stand with science.]]>Tue, 07 Apr 2026 19:13:56 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/how-agentic-ai-reshaping-launch-playbook-pharmahttps://www.pharmexec.com/view/how-agentic-ai-reshaping-launch-playbook-pharma<![CDATA[The agentic model is emerging as a strategic tool to compress analysis timelines, coordinate cross-functional teams and surface competitive intelligence in real time.]]>Tue, 07 Apr 2026 15:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/copay-funds-are-being-misused-at-the-pharmacy-now-there-s-a-way-to-stop-it-in-real-timehttps://www.pharmexec.com/view/copay-funds-are-being-misused-at-the-pharmacy-now-there-s-a-way-to-stop-it-in-real-time<![CDATA[Cindy Baksh, ConnectiveRx, discusses pharma's shift from reactive audits to real-time prevention—protecting billions in copay spend while ensuring support reaches the patients who need it most.]]>Tue, 07 Apr 2026 14:50:27 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/wegovy-hd-now-available-ushttps://www.pharmexec.com/view/wegovy-hd-now-available-us<![CDATA[Novo Nordisk’s U.S. launch of a higher-dose Wegovy formulation highlights Novo's effort to extend efficacy, capture broader patient demand, and reinforce its dominance in the rapidly expanding obesity market.]]>Tue, 07 Apr 2026 14:02:14 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/gilead-enters-5-billion-agreement-acquire-tubulishttps://www.pharmexec.com/view/gilead-enters-5-billion-agreement-acquire-tubulis<![CDATA[Gilead Sciences’ acquisition of Tubulis underscores the intensifying industry focus on antibody-drug conjugates as a key frontier in oncology treatment. ]]>Tue, 07 Apr 2026 13:33:29 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/world-health-day-2026-quotes-that-stand-with-sciencehttps://www.pharmexec.com/view/world-health-day-2026-quotes-that-stand-with-science<![CDATA[Industry leaders highlight how evidence-based decision-making remains central as World Health Day 2026 emphasizes the theme of standing with science.]]>Tue, 07 Apr 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/glp1-users-seek-medical-care-side-effectshttps://www.pharmexec.com/view/glp1-users-seek-medical-care-side-effects<![CDATA[GLP-1 side effects can be serious, and Phenomix CEO Mark Bagnall discusses the impact they can have on patients, who are not always fully educated.]]>Tue, 07 Apr 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/new-federal-market-access-restrictions-optimizing-manufacturer-strategies-pbms-gain-powerhttps://www.pharmexec.com/view/new-federal-market-access-restrictions-optimizing-manufacturer-strategies-pbms-gain-power<![CDATA[Where PBMs fit into the new market access landscape, how pharma companies can respond and the questions that remain.]]>Mon, 06 Apr 2026 19:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-neurocrine-biosciences-agrees-acquire-soleno-therapeuticshttps://www.pharmexec.com/view/daily-neurocrine-biosciences-agrees-acquire-soleno-therapeutics<![CDATA[In today's Pharmaceutical Executive Daily, Neurocrine Biosciences agrees to acquire Soleno Therapeutics for $2.9 billion to gain Vykat XR, the first approved treatment for hyperphagia in Prader-Willi syndrome, BioNTech announces it will close its Singapore vaccine manufacturing facility by February 2027 as declining Covid revenues drive a strategic pivot, and Pharmaceutical Executive examines two emerging frameworks that specialty drug manufacturers are using to protect patient access and benefit savings in a shifting payer environment.]]>Mon, 06 Apr 2026 18:58:14 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/advancing-healthcare-generative-ai-practicehttps://www.pharmexec.com/view/advancing-healthcare-generative-ai-practice<![CDATA[Reliable, domain-specific AI models grounded in validated clinical evidence are emerging as essential to safely scaling generative AI across healthcare applications.]]>Mon, 06 Apr 2026 17:15:15 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/exception-pathways-benefit-optimization-two-approaches-specialty-savingshttps://www.pharmexec.com/view/exception-pathways-benefit-optimization-two-approaches-specialty-savings<![CDATA[The importance of aligning cost control with clinical appropriateness and continuity of care.]]>Mon, 06 Apr 2026 17:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/biontech-closing-singapore-vaccine-manufacturing-plant-2027https://www.pharmexec.com/view/biontech-closing-singapore-vaccine-manufacturing-plant-2027<![CDATA[BioNTech’s decision to close its Singapore manufacturing facility reflects mounting financial pressure, ongoing restructuring efforts, and uncertainty around the pace at which next-generation mRNA therapies will scale. ]]>Mon, 06 Apr 2026 14:55:54 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/neurocrine-enters-2-billion-agreement-acquire-soleno-therapeuticshttps://www.pharmexec.com/view/neurocrine-enters-2-billion-agreement-acquire-soleno-therapeutics<![CDATA[Neurocrine Biosciences’ planned $2.9 billion acquisition of Soleno Therapeutics includes the addition of Vykat XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome.]]>Mon, 06 Apr 2026 13:27:31 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/bringing-bayesian-method-clinical-trials-dr-stacy-lindborghttps://www.pharmexec.com/view/bringing-bayesian-method-clinical-trials-dr-stacy-lindborg<![CDATA[Imunon’s CEO discusses how FDA allowing the Bayesian method impacts innovation in the clinical trial space.]]>Mon, 06 Apr 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/significant-number-glp1-stop-taking-medication-first-yearhttps://www.pharmexec.com/view/significant-number-glp1-stop-taking-medication-first-year<![CDATA[Phenomix CEO Mark Bagnall discusses the reasons for GLP-1 failure and why it’s common for patients to stop taking the medication.]]>Mon, 06 Apr 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-president-trump-imposes-100-tariff-branded-pharmaceuticalshttps://www.pharmexec.com/view/daily-president-trump-imposes-100-tariff-branded-pharmaceuticals<![CDATA[In today's Pharmaceutical Executive Daily, President Trump signs an executive order imposing 100% tariffs on imported patented pharmaceuticals under Section 232, with significant carve-outs for companies that have struck MFN pricing deals or committed to domestic manufacturing, Pfizer and BioNTech halt a large post-marketing Covid-19 vaccine trial in healthy adults aged 50 to 64 after failing to hit enrollment targets, and a new analysis examines how the industry is adapting strategically to a fundamentally transformed U.S. pricing environment.]]>Fri, 03 Apr 2026 18:13:47 GMTPharmExecusPharmExec Articles